These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2057988)

  • 1. Methotrexate disposition following disruption of the blood-brain barrier.
    Markowsky SJ; Zimmerman CL; Tholl D; Soria I; Castillo R
    Ther Drug Monit; 1991 Jan; 13(1):24-31. PubMed ID: 2057988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas.
    Hall WA; Doolittle ND; Daman M; Bruns PK; Muldoon L; Fortin D; Neuwelt EA
    J Neurooncol; 2006 May; 77(3):279-84. PubMed ID: 16314949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma.
    Zylber-Katz E; Gomori JM; Schwartz A; Lossos A; Bokstein F; Siegal T
    Clin Pharmacol Ther; 2000 Jun; 67(6):631-41. PubMed ID: 10872645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of anesthetic choice, PaCO2, and other factors on osmotic blood-brain barrier disruption in rats with brain tumor xenografts.
    Remsen LG; Pagel MA; McCormick CI; Fiamengo SA; Sexton G; Neuwelt EA
    Anesth Analg; 1999 Mar; 88(3):559-67. PubMed ID: 10072006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracarotid administration of short-chain alkylglycerols for increased delivery of methotrexate to the rat brain.
    Erdlenbruch B; Schinkhof C; Kugler W; Heinemann DE; Herms J; Eibl H; Lakomek M
    Br J Pharmacol; 2003 Jun; 139(4):685-94. PubMed ID: 12812991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery.
    Dahlborg SA; Petrillo A; Crossen JR; Roman-Goldstein S; Doolittle ND; Fuller KH; Neuwelt EA
    Cancer J Sci Am; 1998; 4(2):110-24. PubMed ID: 9532413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased delivery and acute toxicity of cranial irradiation and chemotherapy given with osmotic blood-brain barrier disruption in a rodent model: the issue of sequence.
    Remsen LG; McCormick CI; Sexton G; Pearse HD; Garcia R; Neuwelt EA
    Clin Cancer Res; 1995 Jul; 1(7):731-9. PubMed ID: 9816039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers.
    Kroll RA; Pagel MA; Muldoon LL; Roman-Goldstein S; Fiamengo SA; Neuwelt EA
    Neurosurgery; 1998 Oct; 43(4):879-86; discussion 886-9. PubMed ID: 9766316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine.
    Abelson HT; Fosburg MT; Beardsley GP; Goorin AM; Gorka C; Link M; Link D
    J Clin Oncol; 1983 Mar; 1(3):208-16. PubMed ID: 6607976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of tumor cell exposure to [14C]methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: a quantitative autoradiographic study.
    Shapiro WR; Voorhies RM; Hiesiger EM; Sher PB; Basler GA; Lipschutz LE
    Cancer Res; 1988 Feb; 48(3):694-701. PubMed ID: 3335031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unexpected neurotoxicity of etoposide phosphate administered in combination with other chemotherapeutic agents after blood-brain barrier modification to enhance delivery, using propofol for general anesthesia, in a rat model.
    Fortin D; McCormick CI; Remsen LG; Nixon R; Neuwelt EA
    Neurosurgery; 2000 Jul; 47(1):199-207. PubMed ID: 10917363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.
    Fortin D; Desjardins A; Benko A; Niyonsega T; Boudrias M
    Cancer; 2005 Jun; 103(12):2606-15. PubMed ID: 15880378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system.
    Jahnke K; Kraemer DF; Knight KR; Fortin D; Bell S; Doolittle ND; Muldoon LL; Neuwelt EA
    Cancer; 2008 Feb; 112(3):581-8. PubMed ID: 18072268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [ACNU delivery to malignant glioma tissue by osmotic blood brain barrier modification with intracarotid infusion of hyperosmoral mannitol].
    Miyagami M; Kagawa Y; Tsubokawa T
    No Shinkei Geka; 1985 Sep; 13(9):955-63. PubMed ID: 2999632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue.
    Wolfrom C; Hepp R; Hartmann R; Breithaupt H; Henze G
    Eur J Clin Pharmacol; 1990; 39(4):377-83. PubMed ID: 2076721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring of methotrexate delivery in patients with malignant brain tumors after osmotic blood-brain barrier disruption.
    Neuwelt EA; Diehl JT; Vu LH; Hill SA; Michael AJ; Frenkel EP
    Ann Intern Med; 1981 Apr; 94(4 pt 1):449-54. PubMed ID: 6782926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential permeability of a human brain tumor xenograft in the nude rat: impact of tumor size and method of administration on optimizing delivery of biologically diverse agents.
    Neuwelt EA; Barnett PA; McCormick CI; Remsen LG; Kroll RA; Sexton G
    Clin Cancer Res; 1998 Jun; 4(6):1549-55. PubMed ID: 9626476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seizure-promoting effect of blood-brain barrier disruption.
    Marchi N; Angelov L; Masaryk T; Fazio V; Granata T; Hernandez N; Hallene K; Diglaw T; Franic L; Najm I; Janigro D
    Epilepsia; 2007 Apr; 48(4):732-42. PubMed ID: 17319915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood-brain barrier disruption and methotrexate in the treatment of a readily transplantable intracerebral osteogenic sarcoma of rats.
    Cosolo W; Christophidis N
    Cancer Res; 1987 Dec; 47(23):6225-8. PubMed ID: 3119195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maculopathy as a complication of blood-brain barrier disruption in patients with central nervous system lymphoma.
    Galor A; Ference SJ; Singh AD; Lee MS; Stevens GH; Perez VL; Peereboom DM
    Am J Ophthalmol; 2007 Jul; 144(1):45-49. PubMed ID: 17601426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.